BBI Brickell Biotech, Inc. Stock Quote

BBI [NASD]

Index	-	P/E	-	EPS (ttm)	-0.46	Insider Own	0.40%	Shs Outstand	119.38M	Perf Week	2964.38%
Market Cap	546.42M	Forward P/E	-	EPS next Y	-0.19	Insider Trans	0.00%	Shs Float	117.85M	Perf Month	2256.44%
Income	-39.90M	PEG	-	EPS next Q	-0.05	Inst Own	16.10%	Short Float	4.14%	Perf Quarter	1221.73%
Sales	0.50M	P/S	1092.85	EPS this Y	42.40%	Inst Trans	-9.77%	Short Ratio	0.53	Perf Half Y	1351.22%
Book/sh	0.13	P/B	27.46	EPS next Y	-5.00%	ROA	-153.70%	Target Price	1.08	Perf Year	315.31%
Cash/sh	0.11	P/C	31.59	EPS next 5Y	-	ROE	-191.60%	52W Range	0.09 - 5.10	Perf YTD	1459.63%
Dividend	-	P/FCF	-	EPS past 5Y	39.90%	ROI	-160.00%	52W High	-27.22%	Beta	0.23
Dividend %	-	Quick Ratio	4.40	Sales past 5Y	-51.20%	Gross Margin	-	52W Low	3876.42%	ATR	0.39
Employees	16	Current Ratio	4.40	Sales Q/Q	285.20%	Oper. Margin	-	RSI (14)	88.12	Volatility	52.19% 20.46%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	46.50%	Profit Margin	-	Rel Volume	0.02	Prev Close	3.57
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 12 AMC	Payout	-	Avg Volume	9.18M	Price	3.71
Recom	1.50	SMA20	644.81%	SMA50	1078.04%	SMA200	1006.42%	Volume	12,218	Change	3.92%

Aug-28-20

Initiated

Lake Street

Buy

Aug-25-20

Initiated

Oppenheimer

Outperform

Jul-06-22 08:00AM	Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022 GlobeNewswire -10.30%
Jul-01-22 02:02PM	Brickell Biotech Announces 1-For-45 Reverse Stock Split GlobeNewswire -22.22%
May-19-22 08:00AM	Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02 GlobeNewswire
May-17-22 10:53AM	Healthcare Breakthroughs: IDRA, NMLSF, LMLLF, BBI; Life Sciences Leaders Report Latest Advances in Novel Therapeutics for Autism, Oncology, Autoimmune Diseases, and Glaucoma GlobeNewswire
May-12-22 04:01PM	Brickell Biotech Reports First Quarter 2022 Financial Results and Provides Corporate Update GlobeNewswire
May-05-22 04:01PM	Brickell Biotech to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12, 2022 GlobeNewswire -8.12%
May-04-22 10:53AM	BioMed Momentum: NMLSF, BBI, LMLLF, VERU; Life Sciences Leaders Report Latest Advances in New Drug Development for Autism, COVID-19, Oncology, and Glaucoma GlobeNewswire +11.83%
May-03-22 04:02PM	Brickell Biotech Announces Adjournment of Annual Meeting of Stockholders GlobeNewswire
04:01PM	Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals GlobeNewswire
Apr-30-22 08:50AM	Here's Why We're A Bit Worried About Brickell Biotech's (NASDAQ:BBI) Cash Burn Situation Simply Wall St.
Apr-21-22 03:00PM	Monroe® Announces Expanded Parts Coverage for its Quick-Strut® Assemblies and OESpectrum® and Monro-Matic PLUS® Shocks and Struts PR Newswire -14.66%
06:30AM	TENNECO INTRODUCES ADVANCED HYBRID FRICTION MATERIAL COMPOSITES FOR OE CUSTOMERS PR Newswire
Apr-19-22 09:53AM	Healthcare Breakthroughs: AGRX, NMLSF, BBI, LMLLF; BioMed Leaders Report Latest Advances in New Drug Development for Womens Health, Autism, Glaucoma, and Cancer Therapeutics GlobeNewswire +9.66%
Mar-15-22 07:30AM	Brickell Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update GlobeNewswire -7.96%
Mar-10-22 08:00AM	Brickell Biotech Selected for a Late-Breaking Oral Presentation of US Phase 3 Pivotal Cardigan I and Cardigan II Study Results for Sofpironium Bromide Gel, 15% at the 2022 AAD Annual Meeting GlobeNewswire
Mar-08-22 04:05PM	Brickell Biotech to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 15, 2022 GlobeNewswire +7.06%
Feb-02-22 07:30AM	Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inflammatory Diseases from Carna Biosciences GlobeNewswire -5.73%
Nov-09-21 04:05PM	Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Nov-01-21 04:05PM	Brickell Biotech to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9, 2021 GlobeNewswire
06:41AM	Insiders who bought stock earlier this year lose -US$161k as Brickell Biotech, Inc. (NASDAQ:BBI) drops to US$45m Simply Wall St.
Oct-28-21 07:58AM	Brickell Biotech Prices Public Offering of Common Stock GlobeNewswire -25.53%
Oct-27-21 04:32PM	Brickell Biotech Announces Proposed Underwritten Public Offering of Common Stock GlobeNewswire
Oct-07-21 06:55AM	Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary Endpoints, from Both U.S. Phase 3 Pivotal Clinical Studies of Sofpironium Bromide Gel, 15% in Primary Axillary Hyperhidrosis Patients GlobeNewswire
Sep-17-21 08:00AM	Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and its Role in Autoimmunity GlobeNewswire
Sep-08-21 08:30AM	Brickell Biotech to Participate at Upcoming September Conferences GlobeNewswire
Sep-01-21 07:05AM	Brickell Biotech Expands Leadership Team, Appointing Dr. Monica Luchi as Chief Medical Officer GlobeNewswire
07:00AM	Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases GlobeNewswire
Aug-16-21 08:00AM	Brickell Biotech Announces Final Patient Completed Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis GlobeNewswire
Aug-12-21 04:01PM	Brickell Biotech Reports Second Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Aug-05-21 03:00PM	Brickell (BBI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jul-29-21 08:00AM	Brickell Biotech to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12, 2021 GlobeNewswire
Jul-22-21 04:05PM	Brickell Biotech Announces Closing of $8.05 Million Bought Deal Offering of Common Stock, Including Full Exercise of the Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-19-21 10:44PM	Brickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 Million GlobeNewswire
05:25PM	Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock GlobeNewswire
Jul-06-21 08:00AM	Brickell Biotech to Participate at William Blairs Biotech Focus Conference 2021 GlobeNewswire
Jun-30-21 04:12PM	Penny Stocks to Buy Using Technical Analysis for July 2021 Investopedia
Jun-29-21 04:05PM	Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis GlobeNewswire
Jun-24-21 08:00AM	Brickell Biotech Announces Initiation of a Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by its Development Partner, Kaken Pharmaceutical in Japan GlobeNewswire
Jun-21-21 07:30AM	QuestEx Receives Multi-Year Permit for Drilling on the Sofia Property and Commences Exploration Program CNW Group
Jun-01-21 08:00AM	Brickell Biotech Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology GlobeNewswire +6.72%
May-13-21 04:01PM	Brickell Biotech Reports First Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM	Brickell Biotech Inc to Host Earnings Call ACCESSWIRE
May-06-21 03:00PM	Will Brickell (BBI) Report Negative Earnings Next Week? What You Should Know Zacks -7.16%
Apr-29-21 08:00AM	Brickell Biotech to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13, 2021 GlobeNewswire
Apr-27-21 07:30AM	Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis GlobeNewswire
Apr-23-21 10:01AM	Brickell Biotech Reports Results from U.S. Phase 3 Open-Label, Long-Term Safety Study on Chronic Use of Sofpironium Bromide Gel as a Potential Treatment for Primary Axillary Hyperhidrosis GlobeNewswire
Apr-16-21 10:00AM	Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking Research Program during American Academy of Dermatologys 2021 VMX GlobeNewswire
Apr-15-21 08:00AM	Brickell Biotech Announces Publication of its HDSM-Ax Patient Reported Outcome Scale Validation Results in the Journal of Drugs in Dermatology GlobeNewswire
Mar-09-21 04:01PM	Brickell Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update GlobeNewswire +7.02%
01:30PM	Brickell Biotech Inc to Host Earnings Call ACCESSWIRE
Mar-05-21 08:00AM	Brickell Biotech To Host Key Opinion Leader Webinar on the Hyperhidrosis Market GlobeNewswire
Mar-02-21 12:30PM	Will Brickell (BBI) Report Negative Earnings Next Week? What You Should Know Zacks -5.97%
Feb-25-21 04:05PM	Brickell Biotech to Participate in March Virtual Investor Conferences GlobeNewswire -9.85%
Feb-23-21 04:01PM	Brickell Biotech to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on March 9, 2021 GlobeNewswire -12.95%
Jan-19-21 07:00AM	Brickell Biotech Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology GlobeNewswire
Jan-06-21 12:50AM	Reflecting on Brickell Biotech's (NASDAQ:BBI) Share Price Returns Over The Last Year Simply Wall St. -11.48%
Dec-07-20 07:30AM	Brickell Biotech Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study GlobeNewswire
Nov-18-20 07:00AM	Brickell Biotech Announces Launch Date for Sofpironium Bromide Gel, 5% (ECCLOCK®) in Japan by its Development Partner, Kaken Pharmaceutical GlobeNewswire +14.18%
Nov-16-20 08:00AM	Brickell Biotech to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference GlobeNewswire
Nov-12-20 04:01PM	Brickell Biotech Reports Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM	Brickell Biotech Inc to Host Earnings Call ACCESSWIRE
Oct-29-20 08:00AM	Brickell Biotech to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on November 12, 2020 GlobeNewswire
Oct-22-20 08:00PM	Brickell Biotech Announces Pricing of $15.0 Million Underwritten Public Offering GlobeNewswire -13.19%
Sep-29-20 10:30AM	Oppenheimer: These 2 Stocks Are Poised to Surge by Over 100% TipRanks +5.71%
Sep-25-20 07:00AM	Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis Received by its Development Partner, Kaken Pharmaceutical GlobeNewswire
Sep-10-20 04:05PM	Brickell Biotech to Participate in September Virtual Investor Conferences GlobeNewswire
Sep-08-20 07:30AM	AnGes and Brickell Biotech Announce a Collaboration Agreement for the Development of a Novel DNA Vaccine Candidate for COVID-19 in the U.S. GlobeNewswire
Aug-31-20 04:05PM	Brickell Biotech Announces Issuance of New Composition of Matter Patent on Sofpironium Bromide by the Japanese Patent Office GlobeNewswire
Aug-12-20 04:01PM	Brickell Biotech Reports Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Aug-03-20 04:05PM	Brickell Biotech to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 12, 2020 GlobeNewswire
Jun-17-20 10:00PM	Brickell Biotech, Inc. Announces Pricing of $20.1 Million Underwritten Public Offering GlobeNewswire -24.12%
Jun-15-20 06:30AM	Brickell Biotech Announces Positive Phase 3 Pivotal Study Results for Sofpironium Bromide in Japan Released by Development Partner, Kaken Pharmaceutical GlobeNewswire +50.00%
May-31-20 08:04AM	Brickell Biotech (NASDAQ:BBI) Is Arguably In A Tricky Situation Simply Wall St.
May-13-20 04:01PM	Brickell Biotech Reports First Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire +13.25%
May-04-20 04:05PM	Brickell Biotech to Report First Quarter 2020 Financial Results on May 13, 2020 GlobeNewswire
Mar-18-20 04:01PM	Brickell Biotech Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update GlobeNewswire -10.94%
02:30PM	Brickell Biotech Inc to Host Earnings Call ACCESSWIRE
Mar-09-20 04:05PM	Brickell Biotech to Report Fourth Quarter and Full Year 2019 Financial Results on March 18, 2020 GlobeNewswire -7.23%
Mar-04-20 06:30AM	Brickell Biotech Announces Late-Breaking Oral Presentation at 2020 American Academy of Dermatology Annual Meeting by its Asian Partner, Kaken Pharmaceutical, for Sofpironium Bromide GlobeNewswire
Feb-20-20 11:43AM	Heres Why E*Trade (ETFC), Adesto (IOTS) and Brickell Biotech (BBI) Shares Skyrocketed Today TipRanks +68.13%
06:30AM	Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide in Patients with Primary Axillary Hyperhidrosis in the Journal of the American Academy of Dermatology GlobeNewswire
Feb-18-20 06:30AM	Brickell Biotech Announces Settlement of Dispute with Bodor Labs and Entry into Equity Funding Agreements GlobeNewswire +42.24%
Jan-10-20 04:05PM	Brickell Bios Development Partner, Kaken Pharmaceutical, Submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis GlobeNewswire -5.00%
Nov-13-19 04:05PM	Brickell Bio Announces Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Oct-30-19 04:42PM	Brickell Biotech Provides Update on Bodor Labs Complaint and Funding Agreement with NovaQuest GlobeNewswire
Sep-03-19 06:45AM	Brickell Biotech Completes Merger with Vical GlobeNewswire

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HARDY REGINALD L	CHAIRMAN OF THE BOARD	Jul 26	Buy	0.67	100,000	67,420	448,411	Jul 27 04:43 PM
HARDY REGINALD L	CHAIRMAN OF THE BOARD	Jul 23	Buy	0.66	100,000	66,230	348,411	Jul 27 04:43 PM
McAvoy David R.	General Counsel and CCO	Jul 23	Buy	0.67	18,124	12,138	128,879	Jul 27 04:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience